Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1971 2
1972 3
1973 1
1980 1
1995 1
1996 1
1998 3
1999 3
2000 1
2001 2
2002 2
2003 4
2004 7
2005 6
2006 4
2007 3
2008 12
2009 9
2010 7
2011 11
2012 12
2013 9
2014 12
2015 11
2016 11
2017 14
2018 22
2019 11
2020 18
2021 19
2022 20
2023 24
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Results by year

Filters applied: . Clear all
Page 1
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Perl AE, et al. Among authors: onozawa m. Blood. 2022 Jun 9;139(23):3366-3375. doi: 10.1182/blood.2021011583. Blood. 2022. PMID: 35081255 Free PMC article. Clinical Trial.
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.
Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, Barcella M, Spinelli O, Greco R, Crucitti L, Cieri N, Noviello M, Manfredi F, Montaldo E, Ostuni R, Naldini MM, Gentner B, Waterhouse M, Zeiser R, Finke J, Hanoun M, Beelen DW, Gojo I, Luznik L, Onozawa M, Teshima T, Devillier R, Blaise D, Halkes CJM, Griffioen M, Carrabba MG, Bernardi M, Peccatori J, Barlassina C, Stupka E, Lazarevic D, Tonon G, Rambaldi A, Cittaro D, Bonini C, Fleischhauer K, Ciceri F, Vago L. Toffalori C, et al. Among authors: onozawa m. Nat Med. 2019 Apr;25(4):603-611. doi: 10.1038/s41591-019-0400-z. Epub 2019 Mar 25. Nat Med. 2019. PMID: 30911134
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ. Perl AE, et al. Among authors: onozawa m. Transplant Cell Ther. 2023 Apr;29(4):265.e1-265.e10. doi: 10.1016/j.jtct.2022.12.006. Epub 2022 Dec 13. Transplant Cell Ther. 2023. PMID: 36526260 Free PMC article. Clinical Trial.
A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study).
Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Okuno T, Hironaka S, Nozaki I, Ura T, Chin K, Kojima T, Seki S, Sakanaka K, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Takeuchi H, et al. Among authors: onozawa m. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):454-462. doi: 10.1016/j.ijrobp.2022.07.007. Epub 2022 Aug 4. Int J Radiat Oncol Biol Phys. 2022. PMID: 35932949
Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.
Senjo H, Harada S, Kubota SI, Tanaka Y, Tateno T, Zhang Z, Okada S, Chen X, Kikuchi R, Miyashita N, Onozawa M, Goto H, Endo T, Hasegawa Y, Ohigashi H, Ara T, Hasegawa Y, Murakami M, Teshima T, Hashimoto D. Senjo H, et al. Among authors: onozawa m. Blood. 2023 Aug 3;142(5):477-492. doi: 10.1182/blood.2023019875. Blood. 2023. PMID: 37216687
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Goto H, et al. Among authors: onozawa m. Int J Clin Oncol. 2023 Jun;28(6):816-826. doi: 10.1007/s10147-023-02334-w. Epub 2023 Apr 18. Int J Clin Oncol. 2023. PMID: 37071252
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. Among authors: onozawa m. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
[Ara-C].
Onozawa M, Teshima T. Onozawa M, et al. Nihon Rinsho. 2015 Feb;73 Suppl 2:623-7. Nihon Rinsho. 2015. PMID: 25831835 Japanese. No abstract available.
Prostate cancer trends in Asia.
Akaza H, Onozawa M, Hinotsu S. Akaza H, et al. Among authors: onozawa m. World J Urol. 2017 Jun;35(6):859-865. doi: 10.1007/s00345-016-1939-7. Epub 2016 Sep 19. World J Urol. 2017. PMID: 27644231 Review.
[Bing-Neel syndrome successfully treated with tirabrutinib].
Yokoyama K, Ohigashi H, Miyajima T, Miyashita N, Okada S, Hasegawa Y, Sugita J, Onozawa M, Hashimoto D, Teshima T. Yokoyama K, et al. Among authors: onozawa m. Rinsho Ketsueki. 2022;63(8):870-875. doi: 10.11406/rinketsu.63.870. Rinsho Ketsueki. 2022. PMID: 36058857 Japanese.
236 results